nektar - Search News

News

Nektar Therapeutics Stock Doubles

Nektar Therapeutics Is Up 150%: What’s Happening With NKTR Stock?

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin

Investopedia on MSN · 1d

Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a midstage study of its eczema treatment.

Reuters on MSN · 23h

Nektar's lead drug candidate shows promise in eczema trial, shares soar

Nektar Therapeutics said on Tuesday its lead drug candidate met the main goal of a mid-stage study testing the drug in eczema patients, sending its shares up by nearly 140%. In the 393-patient global trial,

BioSpace4h

Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

Zacks.com on MSN1d

Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?

Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

GlobalData on MSN1d

Nektar’s stock doubles on eczema therapy success in Phase IIb study

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

1don MSN

Nektar surges as lead asset succeeds in mid-stage trial for eczema

Nektar Therapeutics (NASDAQ:NKTR) announced Tuesday that its lead asset, rezpegaldesleukin, reached the main goal in a ...

Fierce Biotech1d

Investors sweet on Nektar as phase 2b eczema success doubles share price

Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...

New Atlas10h

New eczema treatment provides relief in Phase 2 human trials

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

13d

Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC

Nektar Therapeutics' REZPEG shows progress in treating atopic dermatitis & alopecia areata. Click here to find out why I rate ...

Nektar Therapeutics Atopic Dermatitis Treatment Meets Primary Endpoint

The Food and Drug Administration in February granted fast track designation for rezpegaldesleukin to treat adults and pediatric patients 12 years and up with moderate to severe atopic dermatitis, the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results